6 analysts offer recommendations for TransMedics Group Inc. (TMDX) stock


The price of TransMedics Group Inc. (NASDAQ: TMDX) closed at $58.93 in the last session, down -1.02% from day before closing price of $59.54. In other words, the price has decreased by -$0.61 from its previous closing price. On the day, 650979 shares were traded. TMDX stock price reached its highest trading level at $59.51 during the session, while it also had its lowest trading level at $57.81.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.



We take a closer look at TMDX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 19.70 and its Current Ratio is at 20.70. In the meantime, Its Debt-to-Equity ratio is 3.48 whereas as Long-Term Debt/Eq ratio is at 3.48.

Upgrades & Downgrades

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 01 when Hassanein Waleed H sold 7,500 shares for $68.26 per share. The transaction valued at 511,920 led to the insider holds 529,191 shares of the business.

Provost Miriam sold 2,708 shares of TMDX for $180,136 on Aug 31. The VP, Global Regulatory Affairs now owns 23,611 shares after completing the transaction at $66.52 per share. On Aug 29, another insider, Weill David, who serves as the Director of the company, bought 2,500 shares for $62.00 each. As a result, the insider paid 155,000 and bolstered with 13,693 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TMDX now has a Market Capitalization of 1.92B and an Enterprise Value of 1.86B. For the stock, the TTM Price-to-Sale (P/S) ratio is 12.64 while its Price-to-Book (P/B) ratio in mrq is 13.21. Its current Enterprise Value per Revenue stands at 12.28 whereas that against EBITDA is -248.49.

Stock Price History:

Over the past 52 weeks, TMDX has reached a high of $99.63, while it has fallen to a 52-week low of $38.86. The 50-Day Moving Average of the stock is 74.04, while the 200-Day Moving Average is calculated to be 71.93.

Shares Statistics:

According to the various share statistics, TMDX traded on average about 667.97K shares per day over the past 3-months and 816.93k shares per day over the past 10 days. A total of 32.55M shares are outstanding, with a floating share count of 31.46M. Insiders hold about 1.50% of the company’s shares, while institutions hold 94.80% stake in the company. Shares short for TMDX as of Aug 30, 2023 were 4.15M with a Short Ratio of 4.15M, compared to 3.55M on Jul 30, 2023. Therefore, it implies a Short% of Shares Outstanding of 12.71% and a Short% of Float of 14.71%.

Earnings Estimates

The company has 6 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.16 for the current quarter, with a high estimate of -$0.06 and a low estimate of -$0.36, while EPS last year was -$0.25. The consensus estimate for the next quarter is -$0.17, with high estimates of $0.06 and low estimates of -$0.45.

Analysts are recommending an EPS of between -$0.1 and -$0.93 for the fiscal current year, implying an average EPS of -$0.44. EPS for the following year is -$0.16, with 5 analysts recommending between $0.59 and -$0.77.

Revenue Estimates

According to 5 analysts, the current quarter’s revenue is expected to be $49.19M. It ranges from a high estimate of $54.8M to a low estimate of $44.7M. As of the current estimate, TransMedics Group Inc.’s year-ago sales were $25.68M, an estimated increase of 91.50% from the year-ago figure. For the next quarter, 5 analysts are estimating revenue of $52.35M, an increase of 66.90% less than the figure of $91.50% in the same quarter last year. There is a high estimate of $59.8M for the next quarter, whereas the lowest estimate is $47.4M.

A total of 6 analysts have provided revenue estimates for TMDX’s current fiscal year. The highest revenue estimate was $208.6M, while the lowest revenue estimate was $184.82M, resulting in an average revenue estimate of $193.74M. In the same quarter a year ago, actual revenue was $93.46M, up 107.30% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $286.61M in the next fiscal year. The high estimate is $302.5M and the low estimate is $270.85M. The average revenue growth estimate for next year is up 47.90% from the average revenue estimate for this year.


Please enter your comment!
Please enter your name here